Quantitation of cytochrome P450 mRNA levels in human skin

Analytical Biochemistry

Volumn 316, Issue 1, 2003, Pages 103-110

  Yengi, Lilian G ^a   Xiang, Qian ^b   Pan, Jinmei ^b,c   Scatina, JoAnn ^b   Kao, John ^b   Ball, Simon E ^b   Fruncillo, Richard ^b   Ferron, Geraldine ^b   Wolf, C Roland ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b PFIZER INC   (United States)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HISTOLOGY; NORMAL DISTRIBUTION; RNA; TISSUE;

CYTOCHROME P450; GENETIC POLYMORPHISMS; GENOTYPING ASSAYS; GENOTYPING METHODS; HEALTHY VOLUNTEERS; HUMAN TISSUES; LIMITS OF DETECTION; MEAN VALUES;

POLYMERASE CHAIN REACTION;

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MESSENGER RNA; RIBOSOME RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME LOCALIZATION; HUMAN; HUMAN TISSUE; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; POISSON DISTRIBUTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; RNA ISOLATION; SKIN;

EID: 0037403060     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-2697(03)00042-3     Document Type: Article

References (37)

1. Nebert D.W. Genes encoding drug-metabolizing enzymes: possible role in human disease. Basic Life Sci. 43:1988;45-64.
2. Wolf C.R., Smith C.A.D., Forman D. Metabolic polymorphisms in carcinogen metabolizing enzymes and cancer susceptibility. Br. Med. Bull. 50:1994;718-731.
3. Kao J., Carver M.P. Cutaneous metabolism of xenobiotics. Drug Metab. Rev. 22:1990;363-410.
4. Jugert F.K., Agarwal R., Kuhn A., Bickers D.R., Merk H.F., Mukhtar H. Multiple cytochrome P450 isozymes in murine skin: induction of P450 A1, 2B, 2E and 3A by dexamethasone. J. Invest. Dermatol. 102:1994;970-975.
5. Watkins P.B., Kolars J.C., Merion R.M., Campbell D.A., Fishman K., Saenger P. Erythromycin and 6B-OH cortisol: studies in 32 patients and in an "anhepatic man" Clin. Res. 32:1989;42A.
6. ′ exonuclease activity of Thermus aquaticus DNA polymerase Proc. Natl. Acad. Sci. USA. 88:1991;7276-7280.
7. Pan J., Xiang Q., Ball S. Use of a novel real-time quantitative reverse transcription-polymerase chain reaction method to study the effects of cytokines on cytochrome P450 mRNA expression in mouse liver. Drug Metab. Dispos. 28:2000;709-713.
8. ′ promoter region of CYP3A4 Clin. Pharmacol. Ther. 66:1999;288-294.
9. Katiyar S.K., Matsui M.S., Mukhtar H. Ultraviolet-B exposure of human skin induces cytochromes P450 1A1 and 1B1. J. Invest. Dermatol. 114:2000;328-333.
10. Shimizu Y., Nakatsuru Y., Ichinose M., Takahashi Y., Kume H., Mimura J., Fujii-Kuriyama Y., Ishikawa T. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc. Natl. Acad. Sci. USA. 97:2000;779-782.
11. Stern R.S., Momtaz K. Skin typing for assessment of skin cancer risk and acute response to UV-B and oral methoxsalen photochemotherapy. Arch. Dermatol. 120:1984;869-873.
12. Ibbotson S.H., Farr P.M. The time-course of psoralen-ultraviolet A (PUVA) erythema. J. Invest. Dermatol. 113:1999;346-350.
13. Watkins P.B. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol. Clin. North Am. 21:1992;511-526.
14. Koskela S., Hakkola J., Hukkanen J., Pelkonen O., Sorri M., Saranen A., Anttila S., Fernandez-Salguero P., Gonzalez F., Raunio H. Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem. Pharmacol. 57:1999;1407-1413.
15. Crespi C.L., Penman B.W., Leakey J.A., Arlotto M.P., Stark A., Parkinson A., Turner T., Steimel D.T., Rudo K., Davies R.L.et al. Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis. 11:1990;1293-1300.
16. Camus A.M., Geneste O., Honkakoski P., Bereziat J.C., Henderson C.J., Wolf C.R., Bartsch H., Lang M.A. High variability of nitrosamine metabolism among individuals: role of cytochrome P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodimethylamine in mice and humans. Mol. Carcinog. 7:1993;268-275.
17. Sutter T.R., Tang Y.M., Hayes C.L., Wo Y.Y., Jabs E.W., Li X., Yin H., Cody C.W., Greenlee W.F. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J. Biol. Chem. 269:1994;13092-13099.
18. Spink D.C., Eugster H.P., Lincoln II D.W., Schuetz J.D., Schuetz E.G., Johnson J.A., Kaminsky L.S., Gierthy J.F. 17 Beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: a comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch. Biochem. Biophys. 293:1992;342-348.
19. Shimada T., Hayes C.L., Yamazaki H., Amin S., Hecht S.S., Guengerich F.P., Sutter T.R. Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Res. 56:1996;2979-2984.
20. Buters J.T.M., Sakai S., Richter T., Pineau T., Alexander D.L., Savas U., Doehmer J., Ward J.M., Jefcoate C.R., Gonzalez F.J. Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethybenz[a]anthracene-induced lymphomas. Proc. Natl. Acad. Sci. USA. 96:1999;1977-1982.
21. Miles J.S., McLaren A.W., Forrester L.M., Glancy M.J., Lang M.A., Wolf C.R. Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem. J. 267:1990;365-371.
22. Fernandez-Salguero P., Gonzalez F.J. The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics. 5:1995;S123-S128.
23. Forrester L.M., Henderson C.J., Glancey M.J., Back D.J., Park B.K., Ball S.E., Kitteringham N.R., McLaren A.W., Miles J.S., Skett P.et al. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem. J. 281(2):1992;359-368.
24. Zaphiropoulos P.G. Exon skipping and circular RNA formation in transcripts of the human cytochrome P-450 2C18 gene in epidermis and of the rat androgen binding protein gene in testis. Mol. Cell. Biol. 17:1997;2985-2993.
25. Goldstein J.A., de Morais S.M. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 4:1994;285-299.
26. Gray I.C., Nobile C., Muresu R., Ford S., Spurr N.K. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics. 28:1995;328-332.
27. Rahman A., Korzekwa K.R., Grogan J., Gonzalez F.J., Harris J.W. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54:1994;5543-5546.
28. Stubbins M.J., Wolf C.R. Vineis P., Lang M., d'Errico A., Carporaso N., Cuzick J., Boffetta P. Metabolic Polymorphisms and Susceptibility to Cancer. 148:1999;271-302 IARC, Lyon, France.
29. Wormhoudt L.W., Commandeur J.N.M., Vermeulen N.P. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione S-transferase and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit. Rev. Toxicol. 29(1):1999;59-124.
30. Botto F., Seree E., El Khyari S., de Sousa G., Massacrier A., Placidi M., Cau P., Pellet W., Rahmani R., Barra Y. Tissue-specific expression and methylation of the human CYP2E1 gene. Biochem. Pharmacol. 48:1994;1095-1103.
31. Bork R.W., Muto T., Beaune P.H., Srivastava P.K., Lloyd R.S., Guengerich F.P. Characterisation of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. J. Biol. Chem. 264:1989;910-919.
32. Lown K.S., Thummel K.E., Benedict P.E., Shen D.D., Turgeon D.K., Berent S., Watkins P.B. The erythromycin breath test predicts the clearance of midazolam. Clin. Pharmacol. Ther. 57:1995;16-24.
33. Murray G.I., Barnes T.S., Sewell H.F., Ewen S.W., Melvin W.T., Burke M.D. The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450. Br. J. Clin. Pharmacol. 25:1988;465-475.
34. de Wildt S.N., Kearns G.L., Leeder S.J., van den Anker J.N. Cytochrome P450 3A: ontogeny and drug disposition. Clin. Pharmacokinet. 37:1999;485-505.
35. Guengerich F.P., Martin M.V., Beaune P.H., Kremers P., Wolff T., Waxman D.J. Characterisation of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261:1996;5051-5060.
36. Forrester L.M., Neal G.E., Judah D.J., Glancey M.J., Wolf C.R. Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B1 metabolism in human liver. Proc. Natl. Acad. Sci. USA. 87:1990;8306-8310.
37. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:1994;414-423.